Pharmacist care in hospital emergency departments: a consensus paper from the Spanish hospital pharmacy and emergency medicine associations.

Objectives: To draft a list of actions and quality indicators for pharmacist care in hospital emergency departments, based on consensus among a panel of experts regarding which actions to prioritize in this setting.

Material And Methods: A panel of experts from the Spanish Society of Hospital Pharmacy (SEFH) and the Spanish Society of Emergency Medicine (SEMES) evaluated a preliminary list of potential actions and quality of care indicators. The experts used a questionnaire to assess the proposals on the basis of available evidence.

DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol.

Objective: The main purpose of this study is to evaluate the potential clinical impact of pharmacogenetic testing on the reduction of the toxicity in patients treated with fluoropyrimidines. This will be achieved by  comparing the frequency of adverse events and the incidence of toxicity of two groups of patients that will differ from each other only in that one  will receive pharmacogenetic counseling. The hypothesis is that availability of a pharmacogenetic report prior to treatment initiation has a positive  effect.

Clinical efficacy and safety of anti PD-1/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer.

Objective: To evaluate the efficacy and safety of anti-PD-1 and anti-PD-L1 immunotherapy agents as monotherapy in patients with non-small cell  lung cancer.

Method: This was a four-year retrospective observational study that included all patients with non-small cell lung cancer treated with  nivolumab, pembrolizumab, and atezolizumab in a third level hospital. Demographic, clinical (ECOG status, stage, PD-L1 expression  level), therapeutic (drug, start date, line of treatment and number of  cycles), efficacy (date and status at the end of follow-up) and toxicity  variables were collected.

Quality of the record of drug-related problems in a database for voluntary adverse event reporting.

Objective: To determine the number and type of errors found in the record of drug-related problems in the SINEA database, an electronic system for voluntary reporting of adverse events in healthcare, in order to quantify the differences between the raw and refined databases, suggest improvements, and determine the need for refining said databases.

Methods: A Pharmacist reviewed the database and refined the adverse events reported from January to August, 2014, considering the "describe_what_happened" field as the gold standard. There was a comparison of the rates of medication errors, both potential and real, adverse reactions, impact on the patient, impact on healthcare, and medications more frequently involved in the raw and refined databases.

Implementation and Evaluation of a Technology System to Improve Safety of the Oncohematology Medication Practices.

OBJECTIVE The objective of the study was to describe the process of implementing a technology system to improve safety and quality in all processes involved in the treatment with parenteral antineoplastic agents within an interdisciplinary team and to analyze the errors detected and avoided thanks to this system at the different stages of the process. MATERIALS AND METHODS Observational and retrospective study where the implementation of an expert technology system in all phases of the therapeutic process is described: prescription, validation, preparation and administration of drugs, in which errors found in the different phases are analysed. A descriptive analysis of the errors recorded in the various stages of the process was carried out during 3 months.